4basebio H1 2026 loss widens to £8.9 million; revenue drops 74.9% to £0.3 million

PUBT · 2d ago
4basebio H1 2026 loss widens to £8.9 million; revenue drops 74.9% to £0.3 million
  • 4basebio posted a loss for the six months ended June 30, 2026 of GBP 8.9 million, widening from GBP 7.8 million.
  • Revenue fell 74.9% to GBP 262,000, while sales orders climbed 210% to GBP 1.2 million.
  • Operating loss widened to GBP 8.9 million from GBP 8.3 million, and basic loss per share deepened to GBP 0.57 from GBP 0.50.
  • Cash and cash equivalents slid to GBP 14.1 million from GBP 17.8 million following a EUR 7 million drawdown under the 2Invest AG loan facility.
  • Chief executive Amy Walker cited strong commercial momentum, with a qualified pipeline of GBP 63 million, up six-fold since Q3 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4BASEBIO plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280201PR_NEWS_PRUKDSCX_0019) on September 28, 2026, and is solely responsible for the information contained therein.